Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
With
Dermira, Inc.
Age
0–17
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have a diagnosis of AD prior to screening as stated in the criteria by the American Academy of Dermatology for at least,
* 12 months if participants are ≥6 years of age
* 6 months if participants are 2 to \<6 years of age
* 3 months if participants are 6 months to \<2 years of age.
Have an EASI score ≥16 at the screening and baseline
Have an IGA score ≥3 (scale of 0 to 4) at the screening and baseline
Have ≥10% BSA of AD involvement at the screening and baseline.
You may not be if
Are currently enrolled or have participated within the last 8 weeks in a clinical study involving an investigational intervention or any other type of medical research judged not to be scientifically or medically compatible with this study.
Treatment with the following prior to the baseline:
An investigational drug within 8 weeks or less than 5 half-lives, whichever is longer.
Dupilumab within 8 weeks. Note: The enrollment of participants with prior use of Dupilumab will be limited to \<20%.
Treatment with a topical investigational drug within 2 weeks prior to the baseline.
Have received a Bacillus Calmette-Guerin vaccination or treatment within less than 4 weeks before randomization.
Clareo Health | A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
